Olanzapine-high potency antipsychotic drug inducing significant weight gain: A case report

Olanzapine-high potency antipsychotic drug inducing significant weight gain: A case report

INTRODUCTION Olanzapine is a second generation antipsychotic (SGA) with a high level of therapeutic effectiveness in schizophrenia and other psychotic disorders. Along with the positive therapeutic effects, an increase of the body weight frequently occurs. According to the literature, the average we...

Full description

Bibliographic Details
Main Authors:	Marić Nađa P., Josifović-Kostić Dragana, Vuković Olivera, Britvić Dubravka, Jašović-Gašić Miroslava
Format:	Article
Language:	English
Published:	Serbian Medical Society 2008-01-01
Series:	Srpski Arhiv za Celokupno Lekarstvo
Subjects:	schizophrenia olanzapine body weight side effects
Online Access:	http://www.doiserbia.nb.rs/img/doi/0370-8179/2008/0370-81790806284M.pdf

Similar Items

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
by: Ita Fitzgerald, et al.
Published: (2021-09-01)

Olanzapine: Association Between a Typical Antipsychotic Drug and Aortic Calcification
by: Chao Zhang, et al.
Published: (2021-09-01)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
by: Okazaki K, et al.
Published: (2017-11-01)

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia
by: Jiahong Liu, et al.
Published: (2021-09-01)

Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double-blind, multicentric trial
by: Sandip Shah, et al.
Published: (2011-01-01)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
by: Yang F, et al.
Published: (2018-12-01)

Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome
by: Popović Irena, et al.
Published: (2015-01-01)

Effect of aripiprazole and olanzapine on the cognitive function in patients with schizophrenia
by: Xiao-Hong Wang
Published: (2020-05-01)

Olanzapine-induced bilateral pedal and pretibial edema: A case report
by: Behice Han Almis, et al.
Published: (2019-06-01)

The incidence of dysrhythmias after administration of the antipsychotic olanzapine
by: Gulač P., et al.
Published: (2016-09-01)

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
by: Jing Huang, et al.
Published: (2020-05-01)

Case of Secondary Tics Associated With Olanzapine in an Adult
by: Eric W. Mills, et al.
Published: (2017-08-01)

Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
by: Jing Huang, et al.
Published: (2020-06-01)

Mechanism of Action of Antipsychotics, Haloperidol and Olanzapine in vitro
by: Mahapatra, Vijaylaxmi
Published: (2014)

Olanzapine as a cause of urinary incontinence: a case report.
by: Mobolaji Usman Dada, et al.
Published: (2012-09-01)

Olanzapine as a Cause of Urinary Incontinence: A Case Report
by: Mobolaji Usman Dada, et al.
Published: (2012-09-01)

Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia
by: Maria-Ioanna Stefanou, et al.
Published: (2020-04-01)

Olanzapine-Induced Neuroleptic Malignant Syndrome
by: Seyedhamze Hosseini, et al.
Published: (2017-05-01)

Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats
by: Marshall, Kay M., et al.
Published: (2009)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
by: Liang Y, et al.
Published: (2017-04-01)

Electrochemical Studies for the Determination of Quetiapine Fumarate and Olanzapine Antipsychotic Drugs
by: Manal A. El-Shal
Published: (2013-08-01)

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients
by: Wei Zhou, et al.
Published: (2019-03-01)

Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox
by: Clemente Garcia-Rizo
Published: (2020-11-01)

Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
by: P N Suresh Kumar, et al.
Published: (2016-01-01)

Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study
by: Subodh Kumar, et al.
Published: (2014-01-01)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
by: Hong Jihyung, et al.
Published: (2012-12-01)

Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial
by: Charles Lung-Cheng Huang, et al.
Published: (2015-05-01)

Hippocampal Shape and Volume Changes with Antipsychotics in Early-Stage Psychotic Illness
by: Daniel eMamah, et al.
Published: (2012-11-01)

The Relationships Between Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients With Schizophrenia Under Olanzapine Treatment
by: Tzu-Hua Wu, et al.
Published: (2021-08-01)

Teratogenicity with olanzapine
by: Sathya Prakash, et al.
Published: (2014-01-01)

Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series
by: Jiri Masopust, et al.
Published: (2019-05-01)

Olanzapine-Induced Hyperprolactinemia: Two Case Reports
by: Pedro Cabral Barata, et al.
Published: (2019-07-01)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
by: Katagiri H, et al.
Published: (2018-04-01)

Analysis of Gut Microbiota and Their Metabolic Potential in Patients with Schizophrenia Treated with Olanzapine: Results from a Six-Week Observational Prospective Cohort Study
by: Justyna Pełka-Wysiecka, et al.
Published: (2019-10-01)

The Effects of Eight-Week Treatment with High Dose Vitamin E on Serum Cholesterol and Triglyceride Level of Patients with Schizophrenia on Olanzapine: A Placebo Controlled Study
by: Firoozeh Raisi, et al.
Published: (2008-03-01)

The Effects of Eight-Week Treatment with High Dose Vitamin E on Serum Cholesterol and Triglyceride Level of Patients with Schizophrenia on Olanzapine: A Placebo Controlled Study
by: Firoozeh Raisi, et al.
Published: (2008-01-01)

Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy
by: Xinyu Fang, et al.
Published: (2020-11-01)

Folic acid, vitamin B12 and homocysteine levels following olanzapine administration in schizophrenia patients
by: Fahmida Hasnat, et al.
Published: (2018-03-01)

Enhancing the aqueous solubility and dissolution of olanzapine using freeze-drying
by: Mudit Dixit, et al.
Published: (2011-12-01)

Olanzapine-induced Weight Gain: An Animal Model
by: Mann, Stephen Wallace
Published: (2009)